253 related articles for article (PubMed ID: 10599469)
21. [Molecular biology studies of bladder cancer].
Bringuier PP; Knopf HJ; Schalken JA; Debruyne FM
Urologe A; 1991 May; 30(3):167-71. PubMed ID: 1871935
[TBL] [Abstract][Full Text] [Related]
22. Quantitative detection of cytokeratin 20 mRNA expression in bladder carcinoma by real-time reverse transcriptase-polymerase chain reaction.
Christoph F; Müller M; Schostak M; Soong R; Tabiti K; Miller K
Urology; 2004 Jul; 64(1):157-61. PubMed ID: 15245962
[TBL] [Abstract][Full Text] [Related]
23. Expression of cell cycle proteins in T1a and T1b urothelial bladder carcinoma and their value in predicting tumor progression.
Mhawech P; Greloz V; Oppikofer C; Szalay-Quinodoz I; Herrmann F
Cancer; 2004 Jun; 100(11):2367-75. PubMed ID: 15160340
[TBL] [Abstract][Full Text] [Related]
24. How to combine the molecular profile with the clinicopathological profile of urothelial neoplastic lesions.
van der Kwast TH
Scand J Urol Nephrol Suppl; 2008 Sep; (218):175-84. PubMed ID: 18815932
[TBL] [Abstract][Full Text] [Related]
25. Early diagnosis and monitoring of superficial transitional cell carcinoma by microsatellite analysis on urine sediment.
Bartoletti R; Dal Canto M; Cai T; Piazzini M; Travaglini F; Gavazzi A; Rizzo M
Oncol Rep; 2005 Mar; 13(3):531-7. PubMed ID: 15706429
[TBL] [Abstract][Full Text] [Related]
26. Prognostic impact of p63 and p53 expression in upper urinary tract transitional cell carcinoma.
Zigeuner R; Tsybrovskyy O; Ratschek M; Rehak P; Lipsky K; Langner C
Urology; 2004 Jun; 63(6):1079-83. PubMed ID: 15183954
[TBL] [Abstract][Full Text] [Related]
27. Association of TSC1/hamartin, 14-3-3sigma, and p27 expression with tumor outcomes in patients with pTa/pT1 urothelial bladder carcinoma.
Mhawech-Fauceglia P; Alvarez V; Fischer G; Beck A; Herrmann FR
Am J Clin Pathol; 2008 Jun; 129(6):918-23. PubMed ID: 18480009
[TBL] [Abstract][Full Text] [Related]
28. Genetic and epigenetic aspects of bladder cancer.
Kim WJ; Quan C
J Cell Biochem; 2005 May; 95(1):24-33. PubMed ID: 15759278
[TBL] [Abstract][Full Text] [Related]
29. Transient receptor potential vanilloid type 2 (TRPV2) expression in normal urothelium and in urothelial carcinoma of human bladder: correlation with the pathologic stage.
Caprodossi S; Lucciarini R; Amantini C; Nabissi M; Canesin G; Ballarini P; Di Spilimbergo A; Cardarelli MA; Servi L; Mammana G; Santoni G
Eur Urol; 2008 Sep; 54(3):612-20. PubMed ID: 17977643
[TBL] [Abstract][Full Text] [Related]
30. Detection of genetic aberrations in bladder cancer using in situ hybridization.
Ramaekers FC; Hopman AH
Ann N Y Acad Sci; 1993 Mar; 677():199-213. PubMed ID: 8098592
[No Abstract] [Full Text] [Related]
31. [A comparative study of DNA measurement of bladder cancer from image cytometry and chromosome aberration in in situ hybridization].
Nemoto R; Nakamura I; Uchida K; Harada M
Gan To Kagaku Ryoho; 1995 Jun; 22 Suppl 2():153-7. PubMed ID: 7611780
[TBL] [Abstract][Full Text] [Related]
32. Minichromosome maintenance proteins 2 and 5 expression in muscle-invasive urothelial cancer: a multivariate survival study including proliferation markers and cell cycle regulators.
Korkolopoulou P; Givalos N; Saetta A; Goudopoulou A; Gakiopoulou H; Thymara I; Thomas-Tsagli E; Patsouris E
Hum Pathol; 2005 Aug; 36(8):899-907. PubMed ID: 16112007
[TBL] [Abstract][Full Text] [Related]
33. Evaluation of CA19-9 as a tumor marker in urothelial malignancy.
Chuang CK; Liao SK
Scand J Urol Nephrol; 2004; 38(5):359-65. PubMed ID: 15764245
[TBL] [Abstract][Full Text] [Related]
34. Ploidy aberrations and agar cloning ability of malignant cells from human bladder carcinoma.
Høstmark J; Farsund T
Anticancer Res; 1984; 4(3):113-6. PubMed ID: 6465847
[TBL] [Abstract][Full Text] [Related]
35. In vivo assessment of urinary bladder malignancy.
Karr JP; Pontes JE; Murphy GP; Gibas Z; Sandberg AA
Prog Clin Biol Res; 1984; 162A():331-46. PubMed ID: 6592614
[No Abstract] [Full Text] [Related]
36. [The relationships among DNA ploidy type determined by laser scanning cytometry, the overexpression of p53 protein and the numerical aberrations of chromosome 7 in bladder cancer].
Kawamura K; Ikeda R; Suzuki K
Hinyokika Kiyo; 2000 Jun; 46(6):377-83. PubMed ID: 10934605
[TBL] [Abstract][Full Text] [Related]
37. DNA flow cytometry: an update of its use in assessing prognosis for transitional cell cancer of the bladder.
Norming U
Semin Urol; 1993 Aug; 11(3):154-63. PubMed ID: 8210836
[No Abstract] [Full Text] [Related]
38. Poorly differentiated transitional cell carcinoma versus leiomyosarcoma of the ureter: different defects in tumour suppressor genes.
Tzen CY; Wu CJ; Huang ZD; Wu TY
Histopathology; 2007 Aug; 51(2):271-3. PubMed ID: 17593211
[No Abstract] [Full Text] [Related]
39. [Urothelial cancers. Cytogenetic and molecular biology principles].
Strohmeyer T
Urologe A; 1994 Mar; 33(2):122-7. PubMed ID: 7909968
[TBL] [Abstract][Full Text] [Related]
40. CD138-positive plasmacytoid urothelial carcinoma of the bladder.
Patriarca C; Di Pasquale M; Giunta P; Bergamaschi F
Int J Surg Pathol; 2008 Apr; 16(2):215-7. PubMed ID: 18417684
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
